AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca is currently conducting a Phase III clinical study titled ‘Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY).’ The study aims to evaluate the safety and efficacy of anifrolumab, a treatment for systemic sclerosis, compared to a placebo. This research is significant as it targets a challenging autoimmune disease affecting the skin and internal organs.
The intervention being tested is anifrolumab, administered as a subcutaneous injection. It is designed to mitigate the symptoms of systemic sclerosis, offering a potential new treatment option for patients.
The study is interventional, with participants randomly assigned to either receive anifrolumab or a placebo in a parallel model. It employs a quadruple masking approach, ensuring that participants, care providers, investigators, and outcomes assessors are unaware of the treatment allocations during the initial 52-week period. The primary purpose is treatment-focused.
The study began on November 8, 2023, with primary completion expected in 2025. The last update was submitted on July 14, 2025. These dates are crucial as they guide the timeline for potential market entry and investor expectations.
This clinical update could positively impact AstraZeneca’s stock performance by enhancing investor confidence in its pipeline for autoimmune diseases. The success of anifrolumab could position AstraZeneca favorably against competitors in the autoimmune treatment market.
The study is ongoing, and further details are available on the ClinicalTrials portal.